Ryotaro Ohkuma

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Correction: Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Journal: Frontiers in immunology

Published: March 10, 2026

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Elevated plasma IgG is associated with improved treatment response and survival in advanced non‑small cell lung cancer patients treated with anti‑PD‑1 therapy.

Journal: Scientific reports

Published: February 05, 2026

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Association of Intratumoral Macrophage Subsets with Treatment Outcomes in Patients with Stage IV Solid Tumors.

Journal: Laboratory investigation; a journal of technical methods and pathology

Published: February 05, 2026

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Efficacy and safety of necitumumab and pembrolizumab combination therapy in advanced non-small-cell lung cancer with ≥50% PD-L1 expression: A nonrandomized phase II trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 31, 2025

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study.

Journal: Biomedicines

Published: October 30, 2025

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Plasma WFDC2 (HE4) as a Predictive Biomarker for Clinical Outcomes in Cancer Patients Receiving Anti-PD-1 Therapy: A Pilot Study.

Journal: Cancers

Published: June 12, 2025

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Vinegar intake in patients undergoing immune checkpoint inhibitor therapy: food frequency questionnaire study.

Journal: Frontiers in immunology

Published: June 03, 2025

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial.

Journal: Nature communications

Published: April 22, 2025

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers.

Journal: Frontiers in oncology

Published: April 18, 2025

Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression.

Journal: Frontiers in immunology

Published: November 15, 2024

Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors.

Veillonella and Streptococcus are associated with aging of the gut microbiota and affect the efficacy of immune checkpoint inhibitors.

Journal: Frontiers in immunology

Published: November 15, 2024

Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefit.

Ki-67 expression in anti-programmed cell death protein-1 antibody-bound CD8+ T cells as a predictor of clinical benefit.

Journal: Discover oncology

Published: October 17, 2024

Showing 1-12 of 43

Last Updated: 09/26/2026